Oct 1 (Reuters) - Array BioPharma Inc:
* Says announces positive interim results of its novel, oral her2 inhibitor,
arry-380 in a phase 1 trial
* Says arry-380 has been well-tolerated
* Says maximum tolerated dose of arry-380 established in this phase 1 trial is
600 mg (twice daily)
* Says arry-380 has shown signs of clinical activity, including the shrinking
of visceral metastases
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Says announces positive interim results of its novel, oral her2 inhibitor,
arry-380 in a phase 1 trial
* Says arry-380 has been well-tolerated
* Says maximum tolerated dose of arry-380 established in this phase 1 trial is
600 mg (twice daily)
* Says arry-380 has shown signs of clinical activity, including the shrinking
of visceral metastases
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.